Abstract:PD-L1/PD-1 blockade therapy shows durable responses to triple-negative breast cancer (TNBC), but the response rate is low. <a class="topic-link" href="/topics/biochemistry-genetics-and-molecular-biology/cd155">CD155</a> promotes tumor metastasis intrinsically and modulates the immune response extrinsically as the ligand of DNAM-1 (costimulatory receptor) and TIGIT/CD96 (coinhibitory receptors). Herein, we verified that TNBC cells coexpressed PD-L1 and CD155. By examining the receptors of PD-L1 and CD155 on TNBC tumor-infiltrating lymphocytes (TILs) over time, we observed that PD-1 and DNAM-1 were upregulated early, whereas CD96 and <a class="topic-link" href="/topics/biochemistry-genetics-and-molecular-biology/tigit">TIGIT</a> were upregulated late in CD8+ TILs. Based on these findings, we developed CD155 siRNA (siCD155)-loaded mPEG-PLGA-PLL (PEAL) nanoparticles (NPs) coated with PD-L1 blocking antibodies (P/PEALsiCD155) to asynchronously block PD-L1 and CD155 in a spatiotemporal manner. P/PEALsiCD155 maximized early-stage CD8+ <a class="topic-link" href="/topics/materials-science/t-cells">T cell</a> <a class="topic-link" href="/topics/biochemistry-genetics-and-molecular-biology/immunosurveillance">immune surveillance</a> against 4T1 tumor, whereas reversed inhibition status of the late stage CD8+ T cells to prevent 4T1 tumor immune escape. In addition, the combination of P/PEALsiCD155 and tumor-specific CD8 T cells induced immunogenic cell death (ICD) of 4T1 cells to further boost immune checkpoint therapy. Most importantly, P/PEALsiCD155 displayed excellent TNBC targeting and induced CD8+ TILs-dominant intratumor antitumor immunity to efficiently inhibit TNBC progression and metastasis with excellent safety in a <a class="topic-link" href="/topics/biochemistry-genetics-and-molecular-biology/syngenic">syngeneic</a> 4T1 orthotopic TNBC tumor model.

Development of Double Strand RNA Mpei Nanoparticles and Application in Treating Invasive Breast Cancer

Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.

Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology

Effective Gene Silencing Mediated by Polypeptide Nanoparticles LAH4-L1-siMDR1 in Multi-Drug Resistant Human Breast Cancer.

Chemotherapy Drugs Derived Nanoparticles Encapsulating Mrna Encoding Tumor Suppressor Proteins to Treat Triple-Negative Breast Cancer.

Treating Metastatic Triple Negative Breast Cancer with CD44/neuropilin Dual Molecular Targets of Multifunctional Nanoparticles.

A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer

Modulating versatile pathways using a cleavable PEG shell and EGFR-targeted nanoparticles to deliver CRISPR-Cas9 and docetaxel for triple-negative breast cancer inhibition

Size-switchable and Dual-Targeting Nanomedicine for Cancer Chemoimmunotherapy by Potentiating Deep Tumor Penetration and Antitumor Immunity

Nanosized Functional Mirna Liposomes and Application in the Treatment of TNBC by Silencing Slug Gene.

Triple Negative Breast Cancer Therapy with CDK1 Sirna Delivered by Cationic Lipid Assisted PEG-PLA Nanoparticles

Membrane-Cloaked Nanoparticles for RNA Interference of β-Catenin in Triple-Negative Breast Cancer

Effective suppression of triple negative breast cancer by paclitaxel nanoparticles conjugated with transmembrane TNF-α monoclonal antibody

Identification of biomimetic nanoplatform-mediated delivery of si-ISG15 for treatment of triple-negative breast cancer

Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA

Intelligent Biomimetic Nanoplatform for Systemic Treatment of Metastatic Triple-Negative Breast Cancer via Enhanced EGFR-Targeted Therapy and Immunotherapy

TGF-β1 and FOXM1 siRNA co-loaded nanoparticles by disulfide crosslinked PEG-PDMAEMA for the treatment of triple-negative breast cancer and its bone metastases in vitro

The Inhibition of Metastasis and Growth of Breast Cancer by Blocking the NF-κB Signaling Pathway Using Bioreducible PEI-based/p65 Shrna Complex Nanoparticles

Efficient TNBC immunotherapy by dual reprogramming tumor-infiltrating dendritic cells and tumor-associated macrophages with stimulus-responsive miR155 nanocomplexes

Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis

Targeted Polymer Lipid Hybrid Nanoparticles for In-Vitro Sirna Therapy in Triple-Negative Breast Cancer